ag-1296 has been researched along with su 11248 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baaj, Y; Cook-Moreau, J; Faucher-Durand, K; Fourcade, L; Funalot, B; Mollard, S; Mousseau, Y; Nizou, A; Plainard, X; Qiu, H; Richard, L; Sturtz, FG | 1 |
1 other study(ies) available for ag-1296 and su 11248
| Article | Year |
|---|---|
Fingolimod potentiates the effects of sunitinib malate in a rat breast cancer model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aorta, Thoracic; Carcinoma 256, Walker; Cell Movement; Cells, Cultured; Drug Screening Assays, Antitumor; Drug Synergism; Female; Fingolimod Hydrochloride; Indoles; Male; Mammary Neoplasms, Experimental; Myocytes, Smooth Muscle; Neoplasm Transplantation; Propylene Glycols; Proto-Oncogene Proteins c-sis; Pyrroles; Rats; Rats, Sprague-Dawley; Receptor, Platelet-Derived Growth Factor beta; Receptors, Lysosphingolipid; Sphingosine; Sphingosine-1-Phosphate Receptors; Statistics, Nonparametric; Sunitinib; Tumor Burden; Tyrphostins | 2012 |